Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotech in 2014—the numbers

Nature Biotechnology volume 33, pages 703–709 (2015)Cite this article

Subjects

2014 was another banner year for public companies, building on the strength of 2013 and adding to the unprecedented biotech bull run.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Public biotech barometers.
Figure 2
Figure 3: NASDAQ biotech index over time.
Figure 4: Global biotech industry financing.

Author information

Authors and Affiliations

  1. Chris Morrison is a freelance writer based in Philadelphia.,

    Chris Morrison

  2. Riku Lähteenmäki is a freelance writer working in Turku, Finland.,

    Riku Lähteenmäki

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary Table

Supplementary Table 1 (XLS 177 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C., Lähteenmäki, R. Public biotech in 2014—the numbers. Nat Biotechnol 33, 703–709 (2015). https://doi.org/10.1038/nbt.3278

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3278

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research